OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy.
OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Singapore, Switzerland, Turkey, Israel and Malaysia. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹.
We believe in our technology and its ability to have a truly positive impact in Oncology.
OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications.
Website link: oncosil.com
References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.
Company’s Keywords:
interventional oncology
<26
<
<
Your request has been submitted successfully.
Own or work here?